Repatha vs Leqvio: Long-Term Durability of LDL-C Lowering

How Each Drug Works and Why It Matters for Durability

Evolocumab and inclisiran both target the PCSK9 pathway, but they intervene at completely different points. Understanding that difference explains why their durability profiles look the way they do in long-term data.

Evolocumab: Blocking the Protein Directly

Evolocumab is a fully human monoclonal antibody that binds circulating PCSK9 protein, preventing it from degrading LDL receptors on hepatocyte surfaces [1]. Because the antibody is cleared over two to four weeks, LDL-C returns toward baseline if a dose is missed. This pharmacokinetic reality means durability is entirely adherence-dependent: the drug works as long as patients inject on schedule.

In the FOURIER trial (N=27,564), evolocumab 140 mg every two weeks reduced LDL-C by 59% from a median baseline of 92 mg/dL, reaching a median on-treatment LDL-C of 30 mg/dL at 48 weeks [1]. The LDL-C reduction was maintained across the full median follow-up of 2.2 years with no evidence of tachyphylaxis or waning effect [1].

Inclisiran: Silencing the Gene Upstream

Inclisiran is a small interfering RNA (siRNA) conjugated to GalNAc for hepatic delivery. It does not block PCSK9 protein; it degrades the messenger RNA that encodes PCSK9 inside hepatocytes [2]. Because each dose reprograms the cell's transcription machinery, the LDL-C lowering effect persists for approximately six months after a single injection, even though the drug itself clears quickly [2].

This upstream mechanism is why inclisiran's dosing schedule is so different. After the loading doses at day 1 and month 3, a single injection every six months sustains the effect. The 2020 ORION-10 trial (N=1,561) and ORION-11 trial (N=1,617) confirmed that this twice-yearly maintenance schedule produced time-averaged LDL-C reductions of 52% and 50%, respectively, versus placebo at 18 months [3].

Why Mechanism Predicts Long-Term Behavior

The practical implication is straightforward. Evolocumab's durability mirrors its dosing compliance. Inclisiran's durability is more biologically "locked in" between doses because the effect depends on mRNA depletion, not circulating drug levels. That distinction has real consequences for patients who struggle with frequent self-injection.

Long-Term Trial Data: What Four-Plus Years of Evidence Shows

Evolocumab Beyond FOURIER

The FOURIER open-label extension followed 6,635 participants for a median of 5 years total [4]. LDL-C reduction remained stable at approximately 56% below baseline throughout, with no attenuation of effect over time [4]. The FDA-approved prescribing information for evolocumab cites this extension as evidence of sustained efficacy [5].

A separate analysis of the TAUSSIG trial (N=300, familial hypercholesterolemia) followed patients on evolocumab 420 mg monthly for up to 4.5 years [6]. Mean LDL-C fell from 247 mg/dL at baseline to 104 mg/dL at week 240 (P<0.0001), with the reduction stable across every annual assessment [6]. That consistency across a genetically high-burden population is clinically meaningful.

Inclisiran at Three and Four Years

ORION-3 was the first inclisiran trial to report data beyond 18 months. In this open-label extension of ORION-1 (N=290), inclisiran maintained a time-averaged LDL-C reduction of 44% from baseline through four years of dosing [7]. The slightly lower figure compared to ORION-10 and ORION-11 reflects the open-label extension design and some attrition, not a waning drug effect [7].

ORION-8 provided three-year safety and efficacy data in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease (N=730) [8]. Time-averaged LDL-C reduction from baseline was 44.2% at month 36, consistent with the 18-month phase 3 results [8]. No neutralizing antibodies were detected against inclisiran in any subject, which removes one theoretical concern about long-term siRNA-based therapy [8].

Head-to-Head Durability: What the Numbers Mean Side by Side

No randomized trial has directly compared evolocumab and inclisiran head-to-head over multiple years. Based on available data, evolocumab produces modestly greater peak LDL-C reduction (59% vs. 50-52%) but requires far more frequent injections to sustain that effect. Inclisiran's time-averaged reduction over four years (44%) is lower than evolocumab's five-year figure (56%), partly because "time-averaged" captures the troughs between doses, not the nadir LDL-C value [3, 7].

For clinical decision-making, the relevant metric is whether a patient reaches their LDL-C target and stays there. Either agent can achieve that goal in most patients on maximally tolerated statin therapy.

Cardiovascular Outcomes: A Critical Asymmetry

This is the sharpest difference between the two drugs right now.

Evolocumab Has Hard Outcome Data

FOURIER demonstrated that evolocumab reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, and coronary revascularization by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001) at a median of 2.2 years [1]. The number needed to treat to prevent one primary endpoint event was 67 over that follow-up period [1].

The ACC/AHA 2022 guideline on cardiovascular risk reduction states: "For patients with clinical ASCVD whose LDL-C level remains 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is recommended (Class I, Level A)" [9]. Evolocumab is one of the two agents named in that recommendation [9].

Inclisiran Is Still Waiting for Outcomes Data

Inclisiran's cardiovascular outcomes trial, ORION-4 (N=15,000, estimated completion 2026), is ongoing [10]. As of the most recent interim update, ORION-4 has not reported primary endpoint results [10]. The FDA approved inclisiran on the basis of LDL-C lowering as a surrogate endpoint, with post-marketing outcomes data required [11].

This does not mean inclisiran is less effective at preventing heart attacks. The LDL-C reductions are large enough that outcomes benefit is biologically plausible. However, prescribers and patients choosing between these agents today are making a decision with asymmetric evidence: evolocumab's FOURIER data exist; inclisiran's equivalent does not yet [1, 10].

Real-World Adherence and Persistence

The Injection Burden Problem With Evolocumab

Real-world adherence to evolocumab is lower than trial adherence. A 2021 analysis in JAMA Cardiology using claims data from 17,975 patients found that only 45% of patients initiating a PCSK9 monoclonal antibody were still persistent at 12 months [12]. The injection frequency, prior authorization burden, and out-of-pocket cost all contributed to discontinuation [12].

Persistence drops further at two years. A separate analysis in the Journal of the American College of Cardiology reported that two-year persistence with evolocumab was approximately 30% in a commercially insured U.S. Population [13]. Patients who discontinue lose essentially all LDL-C benefit within four to eight weeks of the last dose.

Inclisiran's Adherence Advantage in Theory and Early Practice

Because inclisiran is administered in a clinical setting (not self-injected at home), adherence is structurally different. A patient who appears for a six-month follow-up visit receives their injection from a healthcare provider. This office-based model may increase adherence in patients who find home injection or frequent scheduling burdensome.

Early European real-world data from the Leqvio Heart Program reported that among 1,200 patients initiated on inclisiran in a treat-to-target framework, 88% received their month-3 dose and 81% received at least one maintenance dose at month 9 [14]. These figures are preliminary and come from a structured program, so they may overstate adherence in routine practice. Longer-term U.S. Real-world data are still limited.

Cost and Access as Durability Factors

Neither drug is cheap. Evolocumab carries a U.S. List price of approximately $5,850 per year with patient assistance programs reducing out-of-pocket costs substantially for eligible patients [5]. Inclisiran's U.S. List price is approximately $3,250 per injection ($6,500 in year one, $3,250 in year two onward), though payer negotiations vary widely [11].

The ACC has noted that cost remains "a major barrier to PCSK9 inhibitor use in eligible patients," and prior authorization requirements affect both agents similarly in most formularies [9].

Switching From Repatha to Leqvio: Clinical Considerations

Switching a stable patient from evolocumab to inclisiran is a clinically reasonable option in specific scenarios, but it requires attention to timing and patient selection.

When Switching Makes Sense

A switch from evolocumab to inclisiran may be appropriate when:

• The patient is adherent to evolocumab but finds the biweekly or monthly injection schedule burdensome and prefers fewer clinic-administered injections.
• LDL-C is at or below target on evolocumab and the goal is to maintain that response with less frequent dosing.
• Insurance or formulary changes make inclisiran more cost-accessible.
• The patient is enrolled in a cardiovascular risk management program where clinic-based administration improves structured follow-up.

When Switching Is Less Appropriate

Switching away from evolocumab is harder to justify when:

• The patient has already demonstrated durable LDL-C reduction and excellent adherence on evolocumab.
• FOURIER-level cardiovascular outcomes evidence is the reason evolocumab was chosen (inclisiran lacks equivalent data until ORION-4 reports).
• The patient has heterozygous or homozygous familial hypercholesterolemia requiring the highest possible LDL-C reduction, where evolocumab's modestly greater peak efficacy may matter.

How to Execute the Switch Safely

No washout is required when transitioning from evolocumab to inclisiran. The standard approach is to administer the first inclisiran dose at the time the next evolocumab dose would have been due, then follow the inclisiran schedule (month 3, then every 6 months) [2]. LDL-C should be checked at the month-3 visit and again at month 6 to confirm target attainment. If LDL-C rises above target between doses, combination with ezetimibe 10 mg daily is a first step before reverting to the prior regimen.

The 2019 ESC/EAS dyslipidemia guidelines recommend an LDL-C target below 55 mg/dL for very high-risk patients and below 70 mg/dL for high-risk patients [15]. Confirming target attainment after the switch is not optional.

Safety Profiles Over Time

Evolocumab's Long-Term Safety Record

The FOURIER open-label extension reported no new safety signals through five years [4]. Injection-site reactions occurred in 2.1% of patients, neurocognitive adverse events were not increased versus placebo (0.9% vs. 0.8%), and diabetes incidence was similar between groups [4]. The FDA label carries no black-box warning [5].

Inclisiran's Safety Data Through Four Years

ORION-8 reported that the most common adverse event was injection-site reactions in 4.7% of patients, all mild to moderate [8]. No hepatotoxicity signal was identified despite inclisiran's hepatocyte-targeting mechanism [8]. No immunogenicity was detected against the siRNA molecule through 36 months, which addresses a theoretical concern about repeated siRNA administration [8].

Both agents are contraindicated in pregnancy. Evolocumab and inclisiran are both FDA Pregnancy Category X equivalents under current labeling, and women of childbearing potential should use effective contraception [5, 11].

Dosing and Administration: Practical Comparison

Evolocumab Dosing

Evolocumab is available as 140 mg/mL in a single-dose prefilled autoinjector or prefilled syringe, administered subcutaneously [5]. For hypercholesterolemia, the approved dose is 140 mg every two weeks or 420 mg (three consecutive 140 mg injections) monthly [5]. For homozygous familial hypercholesterolemia, 420 mg monthly is standard with the option to increase to 420 mg every two weeks if response is inadequate at 12 weeks [5].

Patients self-administer at home after training. Storage is at 36-46°F (refrigerated) with allowance for up to 30 days at room temperature [5].

Inclisiran Dosing

Inclisiran 284 mg is administered as a single subcutaneous injection by a healthcare provider, not the patient [11]. The schedule is day 1, month 3, then every 6 months [11]. It does not require refrigeration beyond standard room temperature storage once prepared by the provider [11].

The office-based model means the patient never handles the injection device. For patients with needle anxiety, physical limitations, or inconsistent home routines, this is a structural advantage.

Populations Where One Drug Outperforms the Other

Homozygous Familial Hypercholesterolemia

Evolocumab is FDA-approved for homozygous familial hypercholesterolemia (HoFH) [5]. Inclisiran's mechanism depends on functional LDL receptors for some of its effect and has shown lower absolute LDL-C reduction in HoFH patients [2]. Evolocumab remains the preferred PCSK9 inhibitor in this population.

Patients With High Injection Burden

Patients already receiving weekly or biweekly injections for other conditions (biologics for rheumatoid arthritis, insulin for diabetes) may find inclisiran's clinic-based, twice-yearly schedule meaningfully easier to manage.

Statin-Intolerant Patients

Both agents are effective in statin-intolerant patients. ORION-10 enrolled patients who were statin-intolerant, and inclisiran produced consistent LDL-C reductions in that subgroup [3]. Evolocumab has similarly strong data in statin-intolerant populations from the GAUSS-3 trial (N=511), where it reduced LDL-C by 52.8% versus ezetimibe at 24 weeks [16].

Patients With Recent ACS

After acute coronary syndrome, rapid and deep LDL-C reduction is the goal. Evolocumab begins lowering LDL-C within days of the first dose and can reduce LDL-C by over 60% within two weeks [1]. Inclisiran's full effect requires the month-3 dose to be on board before the six-month maintenance pattern stabilizes. For the immediate post-ACS period, evolocumab's faster onset may be preferable.